This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare. This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Eplerenone

December 17, 2024

Therapeutic category

Antihypertensives

Non-proprietary name Eplerenone

Safety measure

PRECAUTIONS should be revised.

Revised language is underlined.

Current			Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following			2. CONTRAINDICATIONS (This drug is contraindicated to the following		
patients.)			patients.)		
<hypertension></hypertension>			<hypertension></hypertension>		
Patients receiving potassium preparations			Patients receiving potassium preparations (excluding potassiun		
			iodide in cases where it is used for prevention/reduction of interna		
			exposure of the thyroid gland to radioactive iodide)		
					<u>iide)</u>
10. INTERACTIONS			10. INTERACTIONS		
10.1 Contraindications for Co-administration (Do not co-administer			10.1 Contraindications for Co-administration (Do not co-administe		
with the following.)			with the following.)		
<hypertension></hypertension>			<hypertension></hypertension>		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Potassium preparations Potassium chloride Potassium gluconate	Serum potassium levels may increase.	Potassium retention effect may be enhanced.	Potassium preparations Potassium chloride Potassium gluconate	Serum potassium levels may increase.	Potassium retention effect may be enhanced.
Potassium aspartate		,	Potassium aspartate		
Potassium iodide			Potassium iodide		
Potassium acetate			(excluding the cases where potassium iodide		
			is used for prevention/		
			reduction of internal		
			exposure of the thyroid gland to radioactive		
			iodide)		
			Potassium acetate		

administered with caution when co-administered with the following.)	administered with caution when co-administered with the following.)		
(N/A)	< <u>Hypertension></u>		
	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
	Potassium iodide (in cases where potassium iodide is used for prevention/ reduction of internal exposure of the thyroid gland to radioactive iodide)	Serum potassium levels may increase. Careful attention should be paid such as monitoring serum potassium levels periodically.	Potassium_ retention effect_ may be enhanced.

(N/A) Not Applicable. No corresponding language is included in the current PRECAUTIONS.